Pluri Inc. Common Stock (PLUR) — Analysis Summary
Pluri Inc. Common Stock (PLUR) has a market cap of $12.23M with year-over-year revenue growth of -24.0%. Net margin stands at -2344.6%. The stock trades at a P/E ratio of -0.5.
Key Takeaways
- Revenue changed -24.0% year-over-year
- Net margin of -2344.6%
- P/E ratio of -0.5
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, PLUR posted revenue growth of -24.0% and trades at a P/E of -0.5.
Pluri Inc. Common Stock (PLUR)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -26.8x — earnings do not cover interest payments
Current ratio at 0.27x — severe short-term liquidity risk
Operating margin at -2454.5% — severe operating losses
Net margin at -2344.6% — losses exceed revenue (possible one-time charges)
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
113
Headquarters
HAIFA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.